Silence Therapeutics Plc Stock Buy Hold or Sell Recommendation
| SLN Stock | USD 4.84 0.34 7.56% |
Considering the 90-day investment horizon and your above-average risk tolerance, our recommendation regarding Silence Therapeutics PLC is 'Strong Sell'. The recommendation algorithm takes into account all of Silence Therapeutics' available fundamental, technical, and predictive indicators you will find on this site.
Check out Silence Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. In addition, we conduct extensive research on individual companies such as Silence and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Silence Therapeutics PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
Silence |
Execute Silence Therapeutics Buy or Sell Advice
The Silence recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Silence Therapeutics PLC. Macroaxis does not own or have any residual interests in Silence Therapeutics PLC or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Silence Therapeutics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Slightly risky | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | About Average | Details | |
Economic Sensitivity | Responds to the market | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Silence Therapeutics Trading Alerts and Improvement Suggestions
| Silence Therapeutics generated a negative expected return over the last 90 days | |
| Silence Therapeutics has high historical volatility and very poor performance | |
| Silence Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the last year's revenue of 25.38 M. Reported Net Loss for the year was (50.31 M) with profit before taxes, overhead, and interest of 7.27 M. | |
| Silence Therapeutics PLC has about 51.56 M in cash with (39.35 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.72. | |
| Roughly 56.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: The Goldman Sachs Group Initiates Coverage on Silence Therapeutics - MarketBeat |
Silence Therapeutics current analysts advice
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Silence analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Silence analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Average Consensus Strong Buy
The consensus estimates and target price estimation comprises individual analyst assessments, and may or may not mutch the Macroaxis buy or sell advice. It is determined by taking an average of all analyst recommendations and classifying them as Strong Buy, Buy, Hold, or Sell.
Silence Therapeutics Returns Distribution Density
The distribution of Silence Therapeutics' historical returns is an attempt to chart the uncertainty of Silence Therapeutics' future price movements. The chart of the probability distribution of Silence Therapeutics daily returns describes the distribution of returns around its average expected value. We use Silence Therapeutics PLC price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Silence Therapeutics returns is essential to provide solid investment advice for Silence Therapeutics.
| Mean Return | -1.62 | Value At Risk | -12.87 | Potential Upside | 8.59 | Standard Deviation | 7.44 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Silence Therapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Silence Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument, such as Silence Therapeutics, soars without any apparent reason. This usually happens because many institutional investors are aggressively trading Silence Therapeutics PLC back and forth among themselves. Companies that invest excess capital in these types of assets may also be included in this term and can influence corporate governance by exercising voting rights in their investments.
| Shares | Eventide Asset Management, Llc | 2024-09-30 | 640 K | Ikarian Capital, Llc | 2024-09-30 | 587.3 K | Parkman Healthcare Partners Llc | 2024-09-30 | 497.9 K | Saturn V Capital Management Llc | 2024-09-30 | 481.1 K | 5am Venture Management, Llc | 2024-09-30 | 476.2 K | Point72 Asset Management, L.p. | 2024-09-30 | 467.8 K | Citadel Advisors Llc | 2024-09-30 | 436.7 K | Woodline Partners Lp | 2024-09-30 | 406.9 K | Cormorant Asset Management, Llc | 2024-09-30 | 400 K | Tcg Crossover Management, Llc | 2024-09-30 | 3 M | Siren, L.l.c. | 2024-09-30 | 2.8 M |
Silence Therapeutics Cash Flow Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change In Cash | 13.9M | 46.1M | (18.7M) | (785K) | (902.8K) | (857.6K) | |
| Free Cash Flow | (11.3M) | 5.5M | (45.9M) | (39.4M) | (35.5M) | (33.7M) | |
| Depreciation | 482K | 496K | 427K | 498K | 572.7K | 601.3K | |
| Other Non Cash Items | (4.7M) | 347K | (559K) | 9.1M | 10.4M | 11.0M | |
| Capital Expenditures | 514K | 1.3M | 440K | 45K | 51.8K | 49.2K | |
| Net Income | (36.0M) | (45.9M) | (47.4M) | (50.3M) | (45.3M) | (43.0M) | |
| End Period Cash Flow | 27.4M | 73.5M | 54.8M | 54.0M | 62.1M | 65.2M | |
| Investments | (41.3M) | 10M | (16.5M) | 16.4M | 18.9M | 19.8M | |
| Change To Netincome | (258K) | 7.5M | 6.9M | 2.8M | 3.2M | 3.4M |
Silence Therapeutics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Silence Therapeutics or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Silence Therapeutics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Silence stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -1.63 | |
β | Beta against Dow Jones | 1.24 | |
σ | Overall volatility | 7.40 | |
Ir | Information ratio | -0.22 |
Silence Therapeutics Volatility Alert
Silence Therapeutics PLC is displaying above-average volatility over the selected time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Silence Therapeutics' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Silence Therapeutics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Silence Therapeutics Fundamentals Vs Peers
Comparing Silence Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Silence Therapeutics' direct or indirect competition across all of the common fundamentals between Silence Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Silence Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Silence Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Silence Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Silence Therapeutics to competition |
| Fundamentals | Silence Therapeutics | Peer Average |
| Return On Equity | -1.03 | -0.31 |
| Return On Asset | -0.27 | -0.14 |
| Operating Margin | (19.73) % | (5.51) % |
| Current Valuation | 46.35 M | 16.62 B |
| Shares Outstanding | 47.21 M | 571.82 M |
| Shares Owned By Insiders | 13.73 % | 10.09 % |
| Shares Owned By Institutions | 55.56 % | 39.21 % |
| Number Of Shares Shorted | 1.3 M | 4.71 M |
| Price To Book | 1.94 X | 9.51 X |
| Price To Sales | 14.07 X | 11.42 X |
| Revenue | 25.38 M | 9.43 B |
| Gross Profit | 7.27 M | 27.38 B |
| EBITDA | (49.78 M) | 3.9 B |
| Net Income | (50.31 M) | 570.98 M |
| Cash And Equivalents | 51.56 M | 2.7 B |
| Cash Per Share | 1.72 X | 5.01 X |
| Total Debt | 272 K | 5.32 B |
| Debt To Equity | 0.02 % | 48.70 % |
| Current Ratio | 3.76 X | 2.16 X |
| Book Value Per Share | 2.00 X | 1.93 K |
| Cash Flow From Operations | (39.35 M) | 971.22 M |
| Short Ratio | 3.97 X | 4.00 X |
| Earnings Per Share | (1.67) X | 3.12 X |
| Target Price | 46.88 | |
| Number Of Employees | 109 | 18.84 K |
| Beta | 1.04 | -0.15 |
| Market Capitalization | 228.52 M | 19.03 B |
| Total Asset | 93.82 M | 29.47 B |
| Retained Earnings | (304.61 M) | 9.33 B |
| Working Capital | 63.25 M | 1.48 B |
| Net Asset | 93.82 M |
Note: Insider Trading [view details]
Silence Therapeutics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Silence . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Silence Therapeutics Buy or Sell Advice
When is the right time to buy or sell Silence Therapeutics PLC? Buying financial instruments such as Silence Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Silence Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Data Storage Thematic Idea Now
Data Storage
Companies making data storages or providing data storage services. The Data Storage theme has 42 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Data Storage Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Silence Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Silence Therapeutics. If investors know Silence will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Silence Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.67) | Revenue Per Share | Quarterly Revenue Growth (0.59) | Return On Assets | Return On Equity |
The market value of Silence Therapeutics PLC is measured differently than its book value, which is the value of Silence that is recorded on the company's balance sheet. Investors also form their own opinion of Silence Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Silence Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Silence Therapeutics' market value can be influenced by many factors that don't directly affect Silence Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Silence Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Silence Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Silence Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.